NCT07510048 Combatting HIV Or Other STIs Early (CHOOSE)
| NCT ID | NCT07510048 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Westat |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-09-16 |
| Primary Completion | 2029-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-09-16 with a primary completion date of 2029-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overarching goal of this project is to optimize the PrEP Choice integrated mHealth package and assess the efficacy and cost of PrEP Choice on PrEP initiation and adherence among young people. It is hypothesized that PrEP Choice will improve HIV PrEP uptake and adherence among young people and will be cost-effective to deliver to young people in the United States (U.S.). This study will also assess the uptake, adherence, and acceptability of DoxyPEP among young people.
Eligibility Criteria
Inclusion Criteria * Age 13-24 years, inclusive; * Self-reports being at increased likelihood for HIV acquisition, defined as having anal sex with a male in their lifetime; * Owns an iOS or Android Smartphone and able to access all elements of the PrEP Choice package; * Not currently on PrEP and interested in learning more about PrEP; * Is not living with HIV; * Weighs at least 35 kg; * Willing to receive PrEP care from a provider at a participating ATN SC; * Able to understand, read, and speak English; * Able to participate at the study site; and * Willing and able to provide written informed consent. * If of legal age or otherwise able to provide independent informed consent as determined by local law and consistent with IRB policies: Willing and able to provide written informed consent for study participation. * If not of legal age or otherwise not able to provide independent informed consent as determined by local law and consistent with IRB policies: Parent or legal guardian is willing and able to provide written informed consent for study participation and potential participant is willing and able to provide written assent for study participation. Exclusion Criteria: * Female; * In a mutually monogamous sexual relationship with a partner not living with HIV for the past 12 months; * Currently participating in an interventional trial of PrEP agents, or prior enrollment in HPTN 083, HPTN 083-01, or any other study of long-acting PrEP (including PURPOSE- 2 lenacapavir study); * Plan to move within 18 months to an area inaccessible to a participating ATN SC; * An employee of the participating SC; or * Any concurrent participation in other clinical trials or behavioral intervention studies without prior approval from the protocol team. * Any other medical, behavioral, or other conditions that in the opinion of the SC Project Lead could interfere with adherence to study procedures or the individual's ability to remain in the study for an 18-month period or compromise interpretation of study results.
Contact & Investigator
Susan Buchbinder
STUDY CHAIR
San Francisco Department of Public Health
Frequently Asked Questions
Who can join the NCT07510048 clinical trial?
This trial is open to male participants only, aged 13 Years or older, up to 24 Years, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07510048 currently recruiting?
Yes, NCT07510048 is actively recruiting participants. Contact the research team at ErinHealey@westat.com for enrollment information.
Where is the NCT07510048 trial being conducted?
This trial is being conducted at San Francisco, United States, Washington D.C., United States, Tampa, United States, Chicago, United States and 2 additional locations.
Who is sponsoring the NCT07510048 clinical trial?
NCT07510048 is sponsored by Westat. The principal investigator is Susan Buchbinder at San Francisco Department of Public Health. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.